Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276872 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
A Phase 2 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02276872 is a Phase 2 study that has completed, run by United Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT02276872, a Phase 2 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2) transitioning from inhaled prostacyclin therapy; or (3) not currently receiving prostacyclin therapy.
Interventions
- DRUG oral treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2017-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02276872
The ClinicalTrials.gov registry entry for NCT02276872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oral treprostinil is the first listed.
NCT02276872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02276872 about?
NCT02276872 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years". This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2) transitioning from inhaled prostacyclin therapy; or (3) not currently re...
What is the current status of trial NCT02276872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-12-18. Estimated completion is 2017-07-20.
What interventions are being tested in trial NCT02276872?
The interventions under investigation include: oral treprostinil (DRUG).
Who is sponsoring clinical trial NCT02276872?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.